Atherosclerotic Change at One Year After Implantation of Endeavor Zotarolimus-Eluting Stent vs. Everolimus-Eluting Stent

Yasuhiro Akazawa, MD; Koshi Matsuo, MD; Yasunori Ueda, MD, PhD; Mayu Nishio, MD, PhD; Akio Hirata, MD, PhD; Mitsutoshi Asai, MD, PhD; Takayoshi Nemoto, MD; Mitsuru Wada, MD; Ayaka Murakami, BSc; Kazunori Kashiwase, MD, PhD; Kazuhisa Kodama, MD, PhD

Background: Atherosclerosis progression is thought to be one of the mechanisms of late stent failure. Atherosclerosis progression is detected as yellow plaque formation on angioscopy. Cypher sirolimus-eluting stent has been reported to accelerate atherosclerosis progression, but the influence of Endeavor zotarolimus-eluting stent (Endeavor-ZES) or Xience everolimus-eluting stent (Xience-EES) on atherosclerosis has not been clarified. Therefore, we examined the serial changes in extent of atherosclerosis after the implantation of Endeavor-ZES or Xience-EES.

Methods and Results: Consecutive patients who received implantation of Endeavor-ZES (n=25) or Xience-EES (n=30) at de novo lesion of native coronary artery and who had successful angioscopy immediately after stent implantation (baseline) and at 1-year follow-up were included in the study. Change in the maximum yellow color grade (grade 0–3) of the stented segment from baseline to follow-up was examined and was compared between Endeavor-ZES and Xience-EES. The maximum yellow color grade decreased significantly from baseline to follow-up in Endeavor-ZES (1.6±1.1 vs. 0.4±0.8, P<0.001), but it did not change in Xience-EES (1.7±1.0 vs. 1.4±0.7, P=0.23). Although the maximum yellow color grade was not different between Endeavor-ZES and Xience-EES at baseline (P=0.72), it was significantly lower in Endeavor-ZES than in Xience-EES at follow-up (P<0.001).

Conclusions: Atherosclerosis evaluated by yellow color of the plaque was significantly reduced at 1 year after Endeavor-ZES implantation, but was not changed after Xience-EES implantation. (Circ J 2014; 78: 1428–1436)

Key Words: Angioscopy; Drug-eluting stent; Neointima; Yellow plaque

Original Article
Ischemic Heart Disease

D rug-eluting stent (DES) compared with bare metal stent (BMS) has reduced early target lesion revascularization (TLR) through an inhibitory effect on neointima hyperplasia but has increased the risk of stent thrombosis and TLR after 1 year (ie, late stent failure). 1 Although the incidence of stent thrombosis and TLR appeared reduced in the newer DES than the first-generation DES, 2–8 the mechanisms of late stent failure are not well understood.

Editorial p 1325

Angioscopy, as a tool of macroscopic pathology in living patients, can be used to evaluate the extent of atherosclerosis according to the presence of yellow plaque. Yellow plaque, especially that of high yellow color grade, is regarded as vulnerable plaque and has been associated with future coronary events. 9–12 Neoatherosclerosis or atherosclerosis progression has been reported as a cause of late stent failure in both DES and BMS. 13 Cypher sirolimus-eluting stent (Cypher-SES) has been reported to accelerate yellow plaque formation. 14 The influence of Endeavor zotarolimus-eluting stent (Endeavor-ZES) or Xience everolimus-eluting stent (Xience-EES) on atherosclerosis progression, however, has not been clarified. Therefore, we examined the serial changes of yellow plaque appearance after the implantation of Endeavor-ZES or Xience-EES.

Methods

Study Design
This was a single-center serial follow-up study to examine the changes in the yellow color of the stent-implanted segment from baseline to 1-year follow-up after the implantation of
Endeavor-ZES (Endeavor stent; Medtronic, Minneapolis, MN, USA) or Xience-EES (Xience V; Abbott Vascular, Santa Clara, CA, USA) using angioscopy. The change of maximum yellow color grade from baseline to follow-up was examined for Endeavor-ZES and Xience-EES, respectively, and was compared between Endeavor-ZES and Xience-EES.

One-year follow-up catheterization was encouraged for all patients who received coronary intervention, but it was not performed when (1) the patient had renal dysfunction; (2) informed consent was not obtained. Baseline and follow-up angioscopy was encouraged for all patients who received DES implantation, but it was not performed when (1) an angioscopic specialist was not available; (2) there was not adequate time for the examination; or (3) informed consent was not obtained. We have a registry of all patients who undergo angioscopy. From this registry, we retrospectively analyzed for this study the consecutive patients who received implantation of Endeavor-ZES or Xience-EES at de novo lesion of native coronary artery and who had successful angioscopy immediately after stent implantation (baseline) and at 1-year follow-up (between May 2010 and July 2012).

Table 1. Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Endeavor-ZES</th>
<th>Xience-EES</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. patients</td>
<td>25</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>21 (84)</td>
<td>25 (83)</td>
<td>0.62</td>
</tr>
<tr>
<td>Age (years)</td>
<td>68±8</td>
<td>66±8</td>
<td>0.32</td>
</tr>
<tr>
<td>Risk factor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>12 (48)</td>
<td>13 (43)</td>
<td>0.47</td>
</tr>
<tr>
<td>Hypertension</td>
<td>21 (84)</td>
<td>29 (97)</td>
<td>0.12</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>22 (88)</td>
<td>23 (77)</td>
<td>0.23</td>
</tr>
<tr>
<td>Current smoking</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Diagnosis for stenting</td>
<td></td>
<td></td>
<td>0.57</td>
</tr>
<tr>
<td>ACS</td>
<td>3 (12)</td>
<td>3 (10)</td>
<td></td>
</tr>
<tr>
<td>Non-ACS</td>
<td>22 (88)</td>
<td>27 (90)</td>
<td></td>
</tr>
<tr>
<td>Target vessel</td>
<td></td>
<td></td>
<td>0.29</td>
</tr>
<tr>
<td>LAD</td>
<td>10 (40)</td>
<td>17 (57)</td>
<td></td>
</tr>
<tr>
<td>LCX</td>
<td>1 (4)</td>
<td>6 (20)</td>
<td></td>
</tr>
<tr>
<td>RCA</td>
<td>14 (56)</td>
<td>7 (23)</td>
<td></td>
</tr>
<tr>
<td>Medication</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statin</td>
<td>19 (76)</td>
<td>23 (77)</td>
<td>0.60</td>
</tr>
<tr>
<td>Aspirin</td>
<td>22 (88)</td>
<td>27 (90)</td>
<td>0.57</td>
</tr>
<tr>
<td>Clopidogrel/Ticlopidine</td>
<td>23 (92)</td>
<td>30 (100)</td>
<td>0.20</td>
</tr>
<tr>
<td>ARB/ACEI</td>
<td>8 (32)</td>
<td>19 (63)</td>
<td>0.20</td>
</tr>
<tr>
<td>β-blocker</td>
<td>8 (32)</td>
<td>14 (47)</td>
<td>0.20</td>
</tr>
</tbody>
</table>

Data given as mean±SD or n (%).
ACEI, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; EES, everolimus-eluting stent; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery; ZES, zotarolimus-eluting stent.

Table 2. Lesion and Procedural Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Endeavor-ZES</th>
<th>Xience-EES</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. target lesions</td>
<td>25</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>Angiographic stenosis (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before intervention</td>
<td>70.3±17.7</td>
<td>64.1±15.9</td>
<td>0.18</td>
</tr>
<tr>
<td>After intervention</td>
<td>11.7±8.8</td>
<td>12.0±7.3</td>
<td>0.89</td>
</tr>
<tr>
<td>At follow-up</td>
<td>21.3±12.1</td>
<td>15.2±6.7</td>
<td>0.03</td>
</tr>
<tr>
<td>TIMI flow grade (0/1/2/3), n</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before intervention</td>
<td>2/1/4/18</td>
<td>3/0/2/25</td>
<td>0.46</td>
</tr>
<tr>
<td>After intervention</td>
<td>0/0/0/25</td>
<td>0/0/0/30</td>
<td>–</td>
</tr>
<tr>
<td>At follow-up</td>
<td>0/0/0/25</td>
<td>0/0/0/30</td>
<td>–</td>
</tr>
<tr>
<td>Stent size (mm)</td>
<td>3.2±0.3</td>
<td>2.8±0.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total stent length (mm)</td>
<td>24.3±13.2</td>
<td>30.3±20.7</td>
<td>0.20</td>
</tr>
<tr>
<td>Maximum inflation pressure (atm)</td>
<td>17±4</td>
<td>17.7±3</td>
<td>0.49</td>
</tr>
<tr>
<td>Procedural success (%)</td>
<td>100</td>
<td>100</td>
<td>–</td>
</tr>
</tbody>
</table>

Data given as mean±SD or n (%).
TIMI, Thrombolysis in Myocardial Infarction. Other abbreviations as in Table 1.
were not included, because we focused on clarifying the angioscopic characteristics of the stented lesion in the patients without early stent failure before 1-year follow-up.

Catheterization was performed via the femoral, brachial, or radial artery approach using a 6-Fr or 7-Fr sheath and catheters. Coronary angiogram was recorded using the Innova Cardiovascular imaging system (GE Healthcare Japan, Tokyo, Japan);
and quantitative coronary angiographic analysis was done with the system. All patients were taking aspirin 100 mg/day and ticlopidine 500 mg/day or clopidogrel 75 mg/day (dual antiplatelet therapy) throughout the study period. GPIIIa inhibitors were not used for any patient, because they were not approved in Japan for clinical use. Hypertension was defined as blood pressure >140/90 mmHg or the use of anti-hypertensive drugs. Diabetes mellitus was defined as fasting blood glucose >126 mg/dl or the use of oral drugs for diabetes mellitus therapy. Acute coronary syndrome (ACS) includes acute myocardial infarction with/without ST elevation defined by the Joint European Society of Cardiology/American College of Cardiology Committee, and unstable angina defined according to the Braunwald classification. This study was approved by the Osaka Police Hospital Ethics Committee. Written informed consent was obtained from all enrolled patients.

**Angioscopy**

The angioscope RX-3310A and MV-5010A (Machida, Tokyo, Japan) and optic fiber DAG-2218LN (Machida) were used. Angioscopic observation of stented lesions was done while blood was cleared away from view by the injection of 3% dextran-40 as we have previously reported. Yellow color was classified into 4 grades (0, white; 1, slight yellow; 2, yellow; and 3, intensive yellow) compared with standard colors as we have previously reported. Neointima coverage was classified into 3 grades (0, no coverage; 1, poor coverage; 2, complete coverage) as we have previously reported. Thrombus was defined as white or red material that had cotton-like or ragged appearance or that presented fragmentation with or without protrusion into the lumen or adherent to the lumen surface. Maximum and minimum neointima coverage grade, maximum yellow color grade, and presence or absence of thrombus was determined for each stented lesion at baseline and at follow-up. The heterogeneity score was defined as maximum–minimum neointima coverage grade to evaluate the heterogeneity of the coverage. Two angioscopy specialists evaluated the angioscopic images blinded to patient characteristics. In the case of disagreement, a third reviewer served as an arbitrator. The inter- and intra-observer reproducibility for the interpretation of angioscopic images was 95% and 95% for stent coverage, 85% and 95% for plaque color, and 90% and 100% for thrombus, respectively.

**Statistical Analysis**

Continuous data are presented as mean±SD. Comparison of maximum yellow color grade between baseline and follow-up was performed by Wilcoxon signed rank test. Comparison between groups was done using unpaired student t-test, chi-squared test, or Mann-Whitney test. To determine the significant factors associated with maximum yellow color grade at follow-up, multivariate stepwise linear regression analysis was done using stent type, age, gender, hypertension, hypercholesterolemia, diabetes mellitus, stenting for ACS, statin use, maximum yellow color grade at baseline, and minimum neointima coverage grade at follow-up as independent variables. P<0.05 was regarded as statistically significant. All analysis was carried out using SPSS 16.0 J for Windows (SPSS, Chicago, IL, USA).

**Results**

**Patients and Lesion Characteristics**

Included were 25 patients (25 lesions) for Endeavor-ZES and 30 patients (30 lesions) for Xience-EES. Follow-up interval was 380±53 days for Endeavor-ZES and 375±33 days for Xience-EES. There was no significant difference in patient, lesion, or procedural characteristics between the Endeavor-ZES and Xience-EES groups (Tables 1,2), except that stent diameter was larger and angiographic stenosis was more severe at follow-up in the Endeavor-ZES than in the Xience-EES group. Type of ACS was unstable angina in all cases, and no patients with acute myocardial infarction were included.
When we analyzed only the patients who received 3.0-mm stent, the degree of reduction in maximum yellow color grade was still larger in Endeavor-ZES than in Xience-EES (1.0 ± 1.0 vs. −0.1 ± 1.3, P=0.03). The changes in maximum yellow color grade are shown in Figure 3.

The prevalence of thrombus decreased significantly from baseline to follow-up in both stents and was not different between the stents (Figure 4). The maximum (1.8 ± 0.4 vs. 1.2 ± 0.4, P<0.001) and minimum (1.3 ± 0.5 vs. 0.8 ± 0.4, P=0.001) coverage grade was significantly better in Endeavor-ZES than in Xience-EES (Figure 5). The heterogeneity score was not different between Endeavor-ZES and Xience-EES (0.52 ± 0.59 vs. 0.40 ± 0.50, P=0.42). Thrombus was detected only in 2 patients at follow-up: 1 patient with Endeavor-ZES had max-
Contributing Factors to Maximum Yellow Grade at Follow-up

On multivariate stepwise linear regression analysis only stent type (Xience-EES=0, Endeavor-ZES=1) was a significant contributor to maximum yellow color grade at follow-up ($B=-1.03$; $P<0.01$). The cumulative analysis of all patients with maximum yellow color grade 2 and minimum coverage grade 0, and 1 patient with Xience-EES had maximum yellow color grade 2 and minimum coverage grade 1 (Figure 6).
95% confidence interval, −1.48 to −0.59; P<0.001), when stent type, age, gender, hypertension, hypercholesterolemia, diabetes mellitus, stenting for ACS, statin use, maximum yellow color grade at baseline, and minimum neointima coverage grade at follow-up were included as independent variables.

**Discussion**

The maximum yellow color grade did not change from baseline to 1-year follow-up when Xience-EES was implanted, but it decreased significantly when Endeavor-ZES was implanted. In other words, atherosclerosis evaluated by yellow plaque was significantly reduced at 1 year after Endeavor-ZES implantation, while it was not changed after Xience-EES implantation.

**Delayed Healing as Cause of Late Stent Failure**

The incidence of thrombus at follow-up in Cypher-SSES has been reported to be as high as 10–40% according to previous studies. This delayed healing or lack of healing with high frequency of thrombogenesis has been regarded as one of the possible mechanisms for thrombotic occlusion or stenosis progression in the first-generation DES. As shown in the present study, however, both Endeavor-ZES and Xience-EES had very low incidence of thrombus, and therefore, delayed healing would not be a major mechanism of late stent failure in those stents. The presence of thrombus has been associated with high yellow color grade and low neointima coverage grade. Indeed, thrombus was detected in 2 patients with grade 2 maximum yellow color grade and grade 0/1 minimum coverage grade in the present study, but the incidence of thrombus was similarly low in both Endeavor-ZES and Xience-EES regardless of the different yellow color grade and different neointima coverage grade. Angioscopy can classify neointima coverage only approximately into 3 grades, and angioscopically poor coverage (grade 0 and 1) may or may not have thin but mature neointima that can prevent thrombus formation. Therefore, it would be reasonable to suggest that Xience-EES has very thin but good neointima that can prevent thrombus formation.

**Neo/Atherosclerosis Progression as Cause of Late Stent Failure**

Development of atherosclerotic plaque and its disruption is known as a cause of ACS after BMS implantation, but it usually takes approximately 5–10 years for the formation of atherosclerotic yellow plaque in the non-atherosclerotic (fibrous) white thick neointima formed over BMS and the resultant development of ACS due to its disruption. Development of neointima hyperplasia after polymer-based SES was not maintained, partly because of persistent inflammatory stimuli and subsequent cellular proliferation. Higo et al reported for the first time in living humans that Cypher-SSES accelerated the formation of atherosclerotic yellow neointima at 10 months, with intramural thrombus being more frequently detected in the newly formed yellow neointima. A recent histopathologic study by Nakazawa et al confirmed the presence of neoatherosclerosis in the neointima after BMS and DES implantation, with a shorter time to develop neointima hyperplasia for DES than BMS. Although Cypher-SSES accelerates the progression of atherosclerosis, as we have previously demonstrated by the increase of yellow color, and Endeavor-ZES causes the stabilization of atherosclerosis, as shown in the present study by the reduction of yellow color, Xience-EES did not significantly cause progression of atherosclerosis in the present study, given that the yellow color was not changed. The reduction of yellow color by Endeavor-ZES would be caused mainly by the formation of thick non-atherosclerotic fibrous white neointima, as in BMS. The formation of thick non-atherosclerotic fibrous white neointima over atherosclerotic lesions plays a role in sealing and shielding that makes the vulnerable plaque stable. In contrast, Xience-EES had very thin neointima that could not seal and shield the yellow plaque under the stent. Another important finding is that Xience-EES did not accelerate the formation of yellow plaque like Cypher-SSES. Yellow plaque formation is accelerated by various coronary risk factors as a process of atherosclerosis progression, and is regressed by various treatments such as statins. Therefore, in combination with these systemic factors and medications, the characteristics of DES may influence the formation of yellow plaques in the stent-implanted segments. We believe that the presence of in-stent yellow plaque at 1-year follow-up, resulting from the combination of these mechanisms, would be a risk for future stent failure after 1 year. Indeed, statin use has been associated with lower risk of late TLR after Cypher-SSES implantation. It has been shown that the coronary segment with peri-stent contrast staining, which is known as a predictor of late stent thrombosis after DES implantation, frequently has yellow plaque (82%) and thrombus (64%).

According to the results of clinical trials with long-term follow-up to 5 years available in previous reports or at the website ClinicalTrial.gov, TLR at 1 and 5 years are 4.9% and 9.4% in Cypher-SSES, 4.4% and 9.1% in Taxus paclitaxel-eluting stent (Taxus-PES), 5.9% and 7.5% in Endeavor-ZES, and 3.4% and 8.9% in Xience-EES. Therefore, the very late stent failure as shown by the yearly TLR between 1 and 5 years is 1.1%/year, 1.2%/year, 0.4%/year, and 1.4%/year in Cypher-SSES, Taxus-PES, Endeavor-ZES, and Xience-EES, respectively, which appears to be lower in Endeavor-ZES than in other DES, although this is not the result of direct head-to-head comparison. A recent report clarified that, in the ENDEAVOR III trial, although higher angiographic restenosis was observed in Endeavor-ZES than in Cypher-SSES in the primary results reported for the 9-month follow-up, cumulative outcomes through 5 years showed that the composite endpoint of major adverse coronary event and the important components of death, as well as cardiac death and myocardial infarction, favored treatment with Endeavor-ZES compared with Cypher-SSES. Furthermore, despite early difference in angiographic outcome, rates of clinical restenosis beyond 9-month follow-up remained stable with Endeavor-ZES compared with Cypher-SSES, resulting in similar late-term efficacy as measured by the need for TLR. The higher incidence of late-term stent failure in Cypher-SSES than in Endeavor-ZES may possibly be explained by the fact that Cypher-SSES accelerates the progression of yellow plaque and Endeavor-ZES induces regression of the yellow color. Judging from the present results, the stability of the stented segments with Xience-EES may be between those of Endeavor-ZES and Cypher-SSES. The difference in long-term clinical outcome between Xience-EES and Endeavor-ZES may not be clarified without randomized trials.

**Angioscopic Findings and Future DES Failure**

According to the accumulated findings described here, we believe that the extent of atherosclerosis in the DES-implanted segment as shown by its yellow color would be associated with future DES failure. In order to demonstrate that the angioscopic findings at 1-year follow-up would be associated with future DES failure, we are now performing a single-center prospective study (DESNOTE study: Detect the Event.
Atherosclerosis After ZES vs. EES Implantation

of very late Stent failure from the drug-eluting stent NOT well covered by nEointima determined on angioscopy). All patients with successful angiography at planned 1-year follow-up after DES implantation without any event of DES failure before the follow-up have been enrolled since 2004 and are clinically followed up at the outpatient clinic. Angiographic findings are yellow color, neointima coverage, and thrombus at the DES-implanted segment. DES failure is defined as (1) cardiac death; (2) myocardial infarction or unstable angina at the target stent; or (3) TLR.

Study Limitations
Although we have demonstrated the changes in yellow color after the implantation of Endeavor-ZES and Xience-EES, it remains to be clarified whether the yellow color is a surrogate endpoint of future stent failure. Therefore, the present results do not indicate the clinical superiority or inferiority of the examined DES. Although patient characteristics were generally similar between the Endeavor-ZES and Xience-EES groups, they were not completely matched, because this was not a randomized trial. Although there was a significant difference in stent diameter between the groups, the degree of reduction in maximum yellow color grade was still larger in Endeavor-ZES than in Xience-EES when we included 3.0-mm stent alone. Although the atherosclerotic change up to 1 year has been clarified in the present study, the change thereafter should be clarified in further investigations. Only a small percentage of all patients who received Endeavor-ZES or Xience-EES were included in the present analysis. Possible selection bias would be that the patients with renal dysfunction and those with small or tortuous coronary artery not suitable for angiography were not included in the present analysis.

Conclusions
Atherosclerosis evaluated by yellow color of the plaque was significantly reduced at 1 year after Endeavor-ZES implantation, but it was not changed after Xience-EES implantation.

Disclosures
The authors have no conflicts of interest.

References


